CurveBeam AI (ASX:CVB) Buyback Yield %: -44.48 (As of Jul. 02, 2026)


What is CurveBeam AI Buyback Yield %?

CurveBeam AI ASX:CVB -20.00% Buyback Yield % is -44.48 as of Jul. 02, 2026. The stock has 5 warning signs investors should review. Among 348 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 88.22% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

CurveBeam AI's current buyback yield was -44.48%.

CurveBeam AI Buyback Yield % Historical Data

* Premium members only.

The historical data trend for CurveBeam AI's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CurveBeam AI Buyback Yield % Chart

CurveBeam AI Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
0.00 0.00 0.00 -45.58 -35.31

CurveBeam AI Semi-Annual Data
Jun21 Dec21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only -17.59 -45.58 -20.40 -35.31 -16.23

ASX:CVB vs ABT, SYK, MDT: Buyback Yield % Comparison

For the Medical Devices subindustry, CurveBeam AI's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CurveBeam AI Buyback Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where CurveBeam AI's Buyback Yield % falls into.


CurveBeam AI Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

CurveBeam AI's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-1.036 + 11.584) / 29.869147
=-35.31%

CurveBeam AI's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.763 + 6.5) / 35.352316
=-16.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -44.48 mean?
CurveBeam AI (ASX:CVB) has a Buyback Yield % of -44.48 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CurveBeam AI and its competitors. According to the industry distribution chart, CurveBeam AI ranks #307 out of 348 companies in the Medical Devices & Instruments industry, placing it in the top 88.2%.
Is CurveBeam AI's Buyback Yield % too high?
CurveBeam AI's current Buyback Yield % is -44.48. Based on the distribution chart, CurveBeam AI ranks #307 out of 348 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #307 out of 348 companies for Buyback Yield %. This places CurveBeam AI in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CurveBeam AI and its competitors. CurveBeam AI's current Buyback Yield % is -44.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Buyback Yield % of -44.48. The current Buyback Yield % is -44.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Buyback Yield % is -44.48 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CurveBeam AI Business Description

Address 10 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.